SEC Filings
FDA Approves GSK's Jemperli For MSI-H Rectal Cancer On 68% Response Rate In Single-Arm Trial
The accelerated approval came ahead of the FDA's target date, but the independent-review result behind the trial's main goal is 47% and still maturing.